CA2959478C - Dihydro- or tetrahydroquinolin-2-0ne derivatives and their use for the treatment of tuberculosis - Google Patents

Dihydro- or tetrahydroquinolin-2-0ne derivatives and their use for the treatment of tuberculosis Download PDF

Info

Publication number
CA2959478C
CA2959478C CA2959478A CA2959478A CA2959478C CA 2959478 C CA2959478 C CA 2959478C CA 2959478 A CA2959478 A CA 2959478A CA 2959478 A CA2959478 A CA 2959478A CA 2959478 C CA2959478 C CA 2959478C
Authority
CA
Canada
Prior art keywords
fluoro
compound
chloro
dihydroquinolin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959478A
Other languages
English (en)
French (fr)
Other versions
CA2959478A1 (en
Inventor
Hiroshi Shimizu
Yoshikazu Kawano
Shunpei Ishikawa
Yukitaka UEMATSU
Toshio Shinohara
Motohiro Itotani
Yoshikazu Haraguchi
Isao Takemura
Atsunori KANESHIGE
Yuya NAKAI
Norimitsu Hariguchi
Yohei Hayashi
Makoto Matsumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54105947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2959478(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CA2959478A1 publication Critical patent/CA2959478A1/en
Application granted granted Critical
Publication of CA2959478C publication Critical patent/CA2959478C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CA2959478A 2014-08-28 2015-08-28 Dihydro- or tetrahydroquinolin-2-0ne derivatives and their use for the treatment of tuberculosis Active CA2959478C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014174528 2014-08-28
JP2014-174528 2014-08-28
PCT/JP2015/004371 WO2016031255A1 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Publications (2)

Publication Number Publication Date
CA2959478A1 CA2959478A1 (en) 2016-03-03
CA2959478C true CA2959478C (en) 2023-09-26

Family

ID=54105947

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959478A Active CA2959478C (en) 2014-08-28 2015-08-28 Dihydro- or tetrahydroquinolin-2-0ne derivatives and their use for the treatment of tuberculosis

Country Status (29)

Country Link
US (2) US10053446B2 (cg-RX-API-DMAC7.html)
EP (1) EP3186240B9 (cg-RX-API-DMAC7.html)
JP (1) JP6625612B2 (cg-RX-API-DMAC7.html)
KR (1) KR102418413B1 (cg-RX-API-DMAC7.html)
CN (1) CN106795117B (cg-RX-API-DMAC7.html)
AP (1) AP2017009788A0 (cg-RX-API-DMAC7.html)
AR (1) AR101704A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015307873B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017003231B1 (cg-RX-API-DMAC7.html)
CA (1) CA2959478C (cg-RX-API-DMAC7.html)
CY (1) CY1122286T1 (cg-RX-API-DMAC7.html)
DK (1) DK3186240T3 (cg-RX-API-DMAC7.html)
EA (1) EA038414B1 (cg-RX-API-DMAC7.html)
ES (1) ES2743788T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191486T2 (cg-RX-API-DMAC7.html)
HU (1) HUE045025T2 (cg-RX-API-DMAC7.html)
IL (1) IL250484B (cg-RX-API-DMAC7.html)
LT (1) LT3186240T (cg-RX-API-DMAC7.html)
MX (1) MX2017002312A (cg-RX-API-DMAC7.html)
MY (1) MY189098A (cg-RX-API-DMAC7.html)
NZ (1) NZ729064A (cg-RX-API-DMAC7.html)
PH (1) PH12017500290B1 (cg-RX-API-DMAC7.html)
PL (1) PL3186240T3 (cg-RX-API-DMAC7.html)
PT (1) PT3186240T (cg-RX-API-DMAC7.html)
SG (1) SG11201700882XA (cg-RX-API-DMAC7.html)
SI (1) SI3186240T1 (cg-RX-API-DMAC7.html)
TW (1) TWI687409B (cg-RX-API-DMAC7.html)
WO (1) WO2016031255A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201700916B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI687409B (zh) * 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
JP6905506B2 (ja) * 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体
WO2019239382A1 (en) 2018-06-15 2019-12-19 Cadila Healthcare Limited Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria
JP2023085582A (ja) * 2020-05-11 2023-06-21 大塚製薬株式会社 ジヒドロキノリノン化合物の共結晶
KR20220022877A (ko) * 2020-08-19 2022-02-28 주식회사 미토이뮨테라퓨틱스 Mabc-R 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN116102537B (zh) * 2021-11-10 2024-10-01 四川大学 一种喹啉酮类衍生物及其制备方法和用途
CN116589448B (zh) * 2023-04-24 2025-10-28 西南交通大学 一种3,4-二氢喹啉酮衍生物及其应用
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Quabodepistat含有組成物
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Quabodepistat含有組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
AR041198A1 (es) 2002-10-11 2005-05-04 Otsuka Pharma Co Ltd Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b] oxaxol, y composiciones farmaceuticas que lo contienen
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 2,3−ジヒドロイミダゾ[2,1−b]オキサゾ−ル化合物
CA2539335A1 (en) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
ZA200602184B (en) * 2003-10-31 2007-10-31 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
BR122018075478B8 (pt) * 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
EP1988077A4 (en) 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2010045987A1 (en) 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
US8293734B2 (en) 2009-07-31 2012-10-23 Global Alliance For Tb Drug Development Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
US9051333B2 (en) 2011-04-15 2015-06-09 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
TWI687409B (zh) * 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
JP6905506B2 (ja) * 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体

Also Published As

Publication number Publication date
BR112017003231A2 (pt) 2017-11-28
AR101704A1 (es) 2017-01-04
PL3186240T3 (pl) 2020-03-31
KR20170043644A (ko) 2017-04-21
PH12017500290A1 (en) 2017-06-28
EP3186240A1 (en) 2017-07-05
AP2017009788A0 (en) 2017-02-28
LT3186240T (lt) 2019-09-10
US20180312488A1 (en) 2018-11-01
JP2017525697A (ja) 2017-09-07
HRP20191486T1 (hr) 2019-11-15
EA038414B1 (ru) 2021-08-25
TW201609658A (zh) 2016-03-16
EP3186240B1 (en) 2019-06-12
CY1122286T1 (el) 2021-01-27
EP3186240B9 (en) 2019-12-04
ES2743788T3 (es) 2020-02-20
US20170253576A1 (en) 2017-09-07
HRP20191486T2 (hr) 2021-09-17
TWI687409B (zh) 2020-03-11
SG11201700882XA (en) 2017-03-30
WO2016031255A1 (en) 2016-03-03
MX2017002312A (es) 2017-05-08
AU2015307873B2 (en) 2020-01-16
NZ729064A (en) 2022-09-30
US10464926B2 (en) 2019-11-05
BR112017003231B1 (pt) 2022-10-11
JP6625612B2 (ja) 2019-12-25
US10053446B2 (en) 2018-08-21
CA2959478A1 (en) 2016-03-03
IL250484B (en) 2020-04-30
PT3186240T (pt) 2019-09-06
EA201790464A1 (ru) 2017-06-30
HUE045025T2 (hu) 2019-12-30
ZA201700916B (en) 2019-06-26
CN106795117A (zh) 2017-05-31
AU2015307873A1 (en) 2017-03-09
PH12017500290B1 (en) 2023-07-19
SI3186240T1 (sl) 2019-10-30
MY189098A (en) 2022-01-25
CN106795117B (zh) 2020-06-26
KR102418413B1 (ko) 2022-07-06
DK3186240T3 (da) 2019-08-26
IL250484A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
CA2959478C (en) Dihydro- or tetrahydroquinolin-2-0ne derivatives and their use for the treatment of tuberculosis
CN103003233B (zh) 新型异羟肟酸衍生物
US8822460B2 (en) Fused cyclopentyl antagonists of CCR2
US11358932B2 (en) N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
CA3172478A1 (en) Bcl-2 inhibitor
US10669283B2 (en) Compound and pharmacologically acceptable salt thereof
CN114206893A (zh) (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
CA3148365A1 (en) Alpha-d-galactopyranoside derivatives
RO108867B1 (ro) Derivati de piridazinamine, procedee si intermediari pentru prepararea lor
US20080275035A1 (en) Nitroimidazole Compounds
ES2553387T3 (es) Compuestos heterocíclicos para el tratamiento o la prevención de trastornos causados por neurotransmisión reducida de serotonina, norepinefrina o dopamina
JP6976691B2 (ja) 医薬組成物
OA18228A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis.
HK1239683A1 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
HK1239683B (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
RU2840112C2 (ru) Производные бензотриазола
MX2008008195A (en) Nitroimidazole compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113

EEER Examination request

Effective date: 20201113